| |
All women (N = 195)
|
Proliferative diagnosis1 (N = 141)
|
Non-proliferative diagnosis2 (N = 54)
|
P-heterogeneity¥
|
|---|
|
Characteristics
|
Mean LTL§
|
(95 % CI) §
|
Mean LTL§
|
(95 % CI) §
|
Mean LTL§
|
(95 % CI) §
| |
|---|
|
Age (years)
| | | | | | |
0.817
|
|
< 45
|
1.27
|
(1.05, 1.55)
|
1.47
|
(1.13, 1.91)
|
1.07
|
(0.80, 1.42)
| |
|
45–49
|
1.35
|
(1.14, 1.60)
|
1.47
|
(1.20, 1.80)
|
1.10
|
(0.81, 1.50)
| |
|
50–54
|
1.39
|
(1.17, 1.64)
|
1.46
|
(1.21, 1.77)
|
1.16
|
(0.82, 1.64)
| |
|
≥ 55
|
1.23
|
(1.04, 1.45)
|
1.31
|
(1.09, 1.58)
|
0.94
|
(0.65, 1.37)
| |
|
P-trend
|
0.774
|
0.423
|
0.745
| |
|
Body mass index (Kg/m2)
| | | | | | |
0.194
|
|
< 25.0
|
1.24
|
(1.10, 1.39)
|
1.35
|
(1.18, 1.55)
|
0.93
|
(0.73, 1.17)
| |
|
25.0–29.9
|
1.29
|
(1.09, 1.52)
|
1.44
|
(1.17, 1.78)
|
1.09
|
(0.83, 1.42)
| |
|
≥ 30
|
1.56
|
(1.29, 1.90)
|
1.57
|
(1.26, 1.96)
|
1.56
|
(1.05, 2.31)
| |
|
P-trend
|
0.058
|
0.248
|
0.030
| |
|
Age at menarche (years)
| | | | | | |
0.743
|
|
≤ 12
|
1.26
|
(1.09, 1.45)
|
1.33
|
(1.13, 1.57)
|
1.01
|
(0.74, 1.37)
| |
|
13
|
1.36
|
(1.17, 1.58)
|
1.53
|
(1.28, 1.83)
|
1.08
|
(0.83, 1.41)
| |
|
≥ 14
|
1.33
|
(1.11, 1.58)
|
1.43
|
(1.17, 1.75)
|
1.08
|
(0.76, 1.53)
| |
|
P-trend
|
0.613
|
0.530
|
0.787
| |
|
Parity
| | | | | | |
0.739
|
|
Parous
|
1.30
|
(1.17, 1.43)
|
1.39
|
(1.24, 1.55)
|
1.07
|
(0.88, 1.30)
| |
|
Nulliparous
|
1.35
|
(1.14, 1.61)
|
1.53
|
(1.23, 1.89)
|
1.08
|
(0.81, 1.44)
| |
|
Age at first birth (years)*
| | | | | | |
0.744
|
|
< 30
|
1.21
|
(1.08, 1.37)
|
1.30
|
(1.13, 1.50)
|
1.00
|
(0.79, 1.26)
| |
|
≥ 30
|
1.51
|
(1.24, 1.83)
|
1.66
|
(1.31, 2.10)
|
1.28
|
(0.90, 1.81)
| |
|
P-trend
|
0.066
|
0.084
|
0.246
| |
|
Menopausal status
| | | | | | |
0.361
|
|
Premenopausal
|
1.37
|
(1.19, 1.57)
|
1.40
|
(1.18, 1.66)
|
1.22
|
(0.98, 1.51)
| |
|
Postmenopausal
|
1.21
|
(0.98, 1.50)
|
1.45
|
(1.15, 1.82)
|
0.74
|
(0.47, 1.17)
| |
|
Age at menopause (years)
| | | | | | |
0.221
|
|
< 45
|
1.37
|
(1.03, 1.84)
|
1.79
|
(1.30, 2.46)
|
0.67
|
(0.39, 1.17)
| |
|
45–49
|
1.19
|
(0.94, 1.52)
|
1.28
|
(0.99, 1.66)
|
1.18
|
(0.68, 2.05)
| |
|
≥ 50
|
1.24
|
(1.04, 1.48)
|
1.31
|
(1.09, 1.58)
|
0.80
|
(0.52, 1.22)
| |
|
P-trend
|
0.655
|
0.166
|
0.654
| |
|
Menopausal hormone therapy use‡
| | | | | | |
0.461
|
|
Never
|
1.13
|
(0.95, 1.35)
|
1.26
|
(1.02, 1.57)
|
0.89
|
(0.60, 1.34)
| |
|
Ever
|
1.49
|
(1.22, 1.80)
|
1.50
|
(1.23, 1.84)
|
1.10
|
(0.60, 2.01)
| |
|
First degree family history of breast cancer
| | | | | | |
0.883
|
|
No
|
1.25
|
(1.13, 1.38)
|
1.35
|
(1.20, 1.51)
|
1.03
|
(0.85, 1.25)
| |
|
Yes
|
1.50
|
(1.27, 1.78)
|
1.64
|
(1.34, 2.00)
|
1.19
|
(0.87, 1.61)
| |
- 1Diagnosis of hyperplasia, in-situ cancer or invasive cancer
- 2Diagnosis of benign or other discrete non-proliferative diagnosis
- §Based on linear regression with the log-transformed of the relative telomere length as outcome. Results are back-transformed. All characteristics were adjusted for age (continuous) and BMI (continuous), except age and BMI respectively
- ¥P-value based on a Wald test in the regression model corresponding to an interaction term of the proliferative disease variable times the corresponding variable (coded in continuous form)
- *Restricted to parous women
- ‡Restricted to post-menopausal women
- The bolded numbers indicate statistical significance results at the 5 % level
